Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totaling 1,300 shares, a decrease of 61.8% from the August 31st total of 3,400 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is currently 0.2 days.

Adlai Nortye Stock Performance

Adlai Nortye stock opened at $1.78 on Friday. Adlai Nortye has a 1 year low of $1.10 and a 1 year high of $3.89. The company’s 50-day moving average is $1.68 and its two-hundred day moving average is $1.76.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.